The Webinar from yesterday. Some key points:
1. Funding with 4.77 million in cash plus R&D being announced next week
2. Phase 2 funding coming from the Department of Defence in America. They have non dilutive funding to not cause dilution
3. AGN works differently to NYR but the mechanism of reducing secondary brain injury is the same
4. Safety data continuing to come through
https://youtu.be/ijO5rj8hkeo?si=MtcKJVJa6Qmysgk0
Ann: Investor Presentation, page-2
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.023(26.4%) |
Mkt cap ! $17.85M | |||
| Open | High | Low | Value | Volume |
| 8.8¢ | 11.5¢ | 8.8¢ | $249.0K | 2.447M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 167181 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 197198 | 6 |
View Market Depth
| Last trade - 12.56pm 03/10/2024 (20 minute delay) ? |
| NYR (ASX) Chart |